Below is the Rosetta Genomics Ltd. (NASDAQ:ROSG) LD MICRO “Main Event” Micro-Cap Growth Conference transcript. The conference took place from December 2-4, 2014 in Los Angeles. Rosetta Genomics Ltd. (NASDAQ:ROSG) is a leading developer and provider of microRNA-based molecular diagnostics.
Kenneth A. Berlin, President and CEO of Rosetta Genomics (NASDAQ:ROSG) have presented a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).
Kenneth A. Berlin:
Good evening , welcome to track three of 5 pm presentation with Rosetta Genomics.
Thank you! Welcome to The Hardy Soul Series here at 5 pm. Nice to see you all. So, at Rosetta Genomics, we provide lab testing services by providing cutting edge diagnostic tests to solve very important unmet medical needs. Now, we are not the only company in this space that does this but we are differentiated and I will tell you why.
There are five things that we do and they all begin with the letter P:
No: 1: We have a platform differentiated platform.
No: 2: We have products on the market.
No: 3. Because of our platform, we have got a robust pipeline of new products that we plan to launch.
No: 4. We have a promotional efforts. We have our own sales reps in the field.
No: 5. Last but certainly not the least ,we are getting paid we have medicare coverage for our leave test.
So a number of companies in this space do some of those 5 things, we and a select few others do all five of those things and we are going to leverage those five capabilities and attributes to grow the business to critical scale in the revenue prospective and profitability prospective and for the next 30 minutes I will explain how we plan to do that.
So here is our disclaimers about forward looking statements and duties to update.
So first lets talk about the space:
The market diagnostic space is a great space to be in. It’s a high growth market. It’s going with the grain where we help need to grow moving from one side that fits all to pay other therapeutics and treatments to the Genetics and Genomics of the patients. As I mentioned one of our edges in this space is our platform. We have the leading Micro RNA biomarker platform, we have the most validated most accurate and most politic platform out there and Micro RNAs are central biology so they are exquisite by our markers.
We have products; we have revenue generating products today. Our lead products that can afford as medicare coverage and we continue to get increase commercial coverage which is important.
We’ve built a leading sales force in the oncology and pathology space and we are leveraging that sales force against new opportunities that we are bringing in from the outside to expand our revenue base. As I mentioned we have a pipeline so not only are we bringing in new products for our sales reps to sell but we are bringing to market our own new products .We plan to launch our thyroid assay next year and our bladder Cancer assay in 2016.
In addition, we have another revenue source and that comes through collaboration with pharma and biotech companies .We have announced several collaborations this year and we are starting for the first time to garner revenues from these collaborations.
And then finally we have a management team that has executed consumer spaces in the past. So let say a few words about the management team. We have 7 board members who are extremely engaged in the business. I mentioned a few of them here Brian Markinson our chair was the CEO King pharmaceutical led them to a successful exit and then did the same with Fougera pharmaceutical but before that he was at Bristol-Myers and was leading the oncology business so he has relevant domain expertise. Roy Davis was at a long time “JNJs” Johnson & Johnson’s he ran their diagnostic business very steep with diagnostics business he is able to give us tremendous guidance on some of the things that we are working on our pipeline as well as our commercialization efforts.